Eduardo Bravo returns to bring European biotech in on the SPAC splurge
The last year’s SPAC boom has been dominated so far by US-based VCs. Now a prominent European biotech executive and a couple investors are getting in on the game.
Eduardo Bravo, the Big Pharma alum and former CEO of the cell therapy company TiGenix, has launched European Biotech Acquisition. Based in Amsterdam (if a SPAC can be said to be based anywhere besides the Cayman Islands and Amazon Web Services), the new shell company will try to raise $100 million and use it to take a European biotech public within 2 years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.